Products from BPS Bioscience require a minimum order value above 400€
Applications: Screen for activators or inhibitors of TIGIT signaling in a cellular context, screen CD155 antibodies for binding affinity, and characterize the biological activity of TIGIT interactions with CD155
Background: TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies.
Description: Recombinant CHO-K1 cells constitutively expressing human CD155 (Poliovirus receptor, Nectin-like protein 5, GenBank accession #NM_006505) and an engineered T cell receptor (TCR) activator.
Host Cell Line: CHO
Mycoplasma Testing: The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
English
Deutsch
